So Entresto is ready to be rolled out in the US with a price tag of around $4,500 a year. Novartis has hinted at an outcomes-based pricing plan but there are no details of any scheme or how it ...

European drugmaker Novartis (NVS), best known for blockbuster drugs like Entresto, Cosentyx, and Kesimpta, just announced a ...

Novartis is thriving with double-digit growth, driven by key drugs in oncology, cardiology, immunology, and neurology. See ...

Sacubitril, valsartan; 6mg/6mg, 15mg/16mg; oral pellets in caps. Entresto Sprinkle is supplied as film-coated oral pellets are round, biconvex in shape, and provided in a hard capsule in the ...

The pharmaceutical sector has been making headlines for large-scale layoffs, department closures and clinical trial failures.

The Federal Circuit reversed finding sufficient written description. The Federal Circuit explained that the written description requirement pertains only to the claims themselves and the construction ...

With the new manufacturing capacity, 100% of its key medicines for U.S. patients will be made in the U.S., Novartis said late ...

Novartis’ Entresto is on course to become the first drug to be approved in the US for a form of heart failure that is notoriously hard to treat effectively, despite missing the mark in a phase 3 ...

Novartis has over 3,000 employees working at its campus in East Hanover, and 12,000 employees nationwide, said Novartis spokesperson Michael Meo. The 427 layoffs will go into effect between June 13 ...